SCHEMBL8709003

SCHEMBL8709003

CCOC(=O)OC1CCN(C)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CYP2D6 P10635 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
ATM Q13315 1/20 0.38
POLB P06746 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SOAT1 P35610 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8708999 1.00 CHRM4 (0.47) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL9330353 0.89 SCN1A (0.49) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL23199841 0.85 CHRM4 (0.54) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL8122822 0.84 SMN1; SMN2 (0.46) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2
Hydrochloric Acid SCHEMBL23199820 0.83 SMN1; SMN2 (0.53) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL16845011 0.80 CHRM4 (0.50) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL1078049 0.79 ALDH1A1 (0.57) HTTALDH1A1GAASOAT1
SCHEMBL4640870 0.79
SCHEMBL12321236 0.79 SMN1; SMN2 (0.57) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL30142083 0.79 SMN1; SMN2 (0.57) CHRM4CHRM5CHRM1CHRM3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US claimed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP claimed
EP-0844000-A1 Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis SANKYO COMPANY LIMITED (JP) 1998-05-27 EP disclosed
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP disclosed